Skip to main content
[Preprint]. 2022 Mar 30:rs.3.rs-1490282. [Version 1] doi: 10.21203/rs.3.rs-1490282/v1

Figure 1.

Figure 1

Validation and invalidation of dieckol and PGG as SARS-CoV-2 Mpro and PLpro inhibitors. (A) Flip-GFP Mpro assay results of dieckol and PGG. GC376 was included as a positive control. (B) FRET assay results of PGG against SARS-CoV-2 Mpro, SARS-CoV-2 PLpro, SARS-CoV PLpro, and MERS-CoV PLpro. (C) Thermal shift assay characterization of the binding of PGG to SARS-CoV-2 PLpro. (D) Flip-GFP PLpro assay result of PGG. The results are mean ± standard deviation of two repeats.